JO3044B1 - نظام تناول جرعة لمنبه مستقبل s1p - Google Patents

نظام تناول جرعة لمنبه مستقبل s1p

Info

Publication number
JO3044B1
JO3044B1 JOP/2009/0495A JOP20090495A JO3044B1 JO 3044 B1 JO3044 B1 JO 3044B1 JO P20090495 A JOP20090495 A JO P20090495A JO 3044 B1 JO3044 B1 JO 3044B1
Authority
JO
Jordan
Prior art keywords
dosage regimen
receptor stimulant
dosage
daily dosage
receptor
Prior art date
Application number
JOP/2009/0495A
Other languages
English (en)
Inventor
Legangneux Eric
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41435196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3044(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3044B1 publication Critical patent/JO3044B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

معدلات او منبهات مستقبل S1P يتم تعاطيها باتباع نظام تناول الجرعة والذي بمقتضاه خلال ايام المعالجة المبدئية تكون الجرعة اليومية أقل من الجرعة اليومية القياسية.
JOP/2009/0495A 2008-12-22 2009-12-21 نظام تناول جرعة لمنبه مستقبل s1p JO3044B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967308P 2008-12-22 2008-12-22
EP09167209 2009-08-04

Publications (1)

Publication Number Publication Date
JO3044B1 true JO3044B1 (ar) 2016-09-05

Family

ID=41435196

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0495A JO3044B1 (ar) 2008-12-22 2009-12-21 نظام تناول جرعة لمنبه مستقبل s1p

Country Status (34)

Country Link
US (2) US8492441B2 (ar)
EP (1) EP2379069B1 (ar)
JP (2) JP5657565B2 (ar)
KR (1) KR101660555B1 (ar)
CN (2) CN102264363A (ar)
AR (1) AR074825A1 (ar)
AU (1) AU2009331582B2 (ar)
BR (1) BRPI0923213A2 (ar)
CA (3) CA2747992C (ar)
CY (2) CY1116321T1 (ar)
DK (1) DK2379069T3 (ar)
ES (1) ES2538413T3 (ar)
FR (1) FR20C1022I2 (ar)
HR (1) HRP20150567T1 (ar)
HU (2) HUE026400T2 (ar)
IL (2) IL294658A (ar)
JO (1) JO3044B1 (ar)
LT (1) LTC2379069I2 (ar)
LU (1) LUC00160I2 (ar)
MA (1) MA32907B1 (ar)
MX (2) MX367667B (ar)
NL (1) NL301046I2 (ar)
NO (1) NO2020017I1 (ar)
NZ (1) NZ593427A (ar)
PL (1) PL2379069T3 (ar)
PT (1) PT2379069E (ar)
RU (1) RU2561681C2 (ar)
SG (1) SG171888A1 (ar)
SI (1) SI2379069T1 (ar)
TN (1) TN2011000281A1 (ar)
TW (1) TWI472327B (ar)
UY (1) UY32350A (ar)
WO (1) WO2010072703A1 (ar)
ZA (1) ZA201104102B (ar)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
AU2009273259B2 (en) * 2008-07-23 2013-05-02 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
AR074826A1 (es) 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
CA2794607A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
PH12013501442B1 (en) 2011-01-07 2018-04-20 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
HRP20200883T1 (hr) 2012-08-17 2020-09-04 Actelion Pharmaceuticals Ltd. Postupak za pripremanje (2z,5z)-5-(3-kloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međuproizvodi koji se koriste u navedenom postupku
EP3199947A3 (en) * 2013-04-04 2017-09-13 Novartis AG Identifying patient response to s1p receptor modulator administration
EP4074312B1 (en) 2014-04-10 2026-02-25 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
EP3129006B1 (en) * 2014-04-10 2021-01-27 Novartis AG Immunosuppressant formulation
EA036075B1 (ru) 2014-12-11 2020-09-23 Актелион Фармасьютиклз Лтд Схема дозирования для селективного агониста рецептора s1p1
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
RU2020114751A (ru) * 2017-09-29 2021-10-29 Новартис Аг Схема введения доз сипонимода
EP3687530A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
JP2024506041A (ja) 2021-02-08 2024-02-08 ボシュ ヘルス アイルランド リミテッド 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2025134072A1 (en) 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1176819A (zh) * 1997-09-03 1998-03-25 王树生 一种解酒饮料及其制备方法
NZ560662A (en) 2002-05-16 2009-09-25 Novartis Ag Use of EDG receptor binding agents in cancer
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US20050095292A1 (en) * 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
CN1913892A (zh) 2003-12-17 2007-02-14 大日本住友制药株式会社 药物组合物及联合药物
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
CA2589265A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
JP2009507047A (ja) * 2005-09-09 2009-02-19 ラボファーム インコーポレイテッド 持続性薬物放出組成物
WO2008072056A1 (en) * 2006-12-14 2008-06-19 Pfizer Limited Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
TW200927142A (en) * 2007-10-12 2009-07-01 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators

Also Published As

Publication number Publication date
LTC2379069I2 (lt) 2022-05-25
HUS2000017I1 (hu) 2020-07-28
HUE026400T2 (en) 2016-06-28
PL2379069T3 (pl) 2015-08-31
WO2010072703A1 (en) 2010-07-01
ES2538413T3 (es) 2015-06-19
TWI472327B (zh) 2015-02-11
IL294658A (en) 2022-09-01
JP2012513378A (ja) 2012-06-14
LTPA2020513I1 (lt) 2020-07-27
ZA201104102B (en) 2012-02-29
LUC00160I2 (ar) 2021-07-06
UY32350A (es) 2010-04-30
CN102264363A (zh) 2011-11-30
NO2020017I1 (no) 2020-06-17
RU2561681C2 (ru) 2015-08-27
SG171888A1 (en) 2011-07-28
CA3105857C (en) 2023-08-01
SI2379069T1 (sl) 2015-07-31
AU2009331582A1 (en) 2011-06-30
JP5941110B2 (ja) 2016-06-29
JP2015038097A (ja) 2015-02-26
CA2747992A1 (en) 2010-07-01
HRP20150567T1 (hr) 2015-08-14
EP2379069A1 (en) 2011-10-26
CY1116321T1 (el) 2017-02-08
BRPI0923213A2 (pt) 2016-01-26
JP5657565B2 (ja) 2015-01-21
US20110039818A1 (en) 2011-02-17
DK2379069T3 (en) 2015-06-08
CA3105857A1 (en) 2010-07-01
TW201028147A (en) 2010-08-01
CA2981830A1 (en) 2010-07-01
US8492441B2 (en) 2013-07-23
CY2020014I1 (el) 2020-11-25
MA32907B1 (ar) 2011-12-01
MX367667B (es) 2019-08-30
CY2020014I2 (el) 2020-11-25
AR074825A1 (es) 2011-02-16
NL301046I1 (nl) 2020-06-17
KR101660555B1 (ko) 2016-09-27
LUC00160I1 (ar) 2020-06-19
AU2009331582B2 (en) 2014-03-13
US20130281712A1 (en) 2013-10-24
FR20C1022I2 (fr) 2021-06-11
CA2747992C (en) 2017-11-07
IL213347B (en) 2019-11-28
PT2379069E (pt) 2015-07-03
IL213347A0 (en) 2011-07-31
TN2011000281A1 (en) 2012-12-17
FR20C1022I1 (ar) 2020-07-31
NZ593427A (en) 2013-11-29
CN105213372A (zh) 2016-01-06
KR20110106399A (ko) 2011-09-28
HK1159524A1 (en) 2012-08-03
EP2379069B1 (en) 2015-03-04
MX2011006625A (es) 2011-09-28
NL301046I2 (nl) 2020-07-29

Similar Documents

Publication Publication Date Title
JO3044B1 (ar) نظام تناول جرعة لمنبه مستقبل s1p
TN2011000272A1 (en) Dosage regimen for a s1p agonist
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
PH12017501495A1 (en) Dosage regimen of an s1p receptor modulator
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
BRPI0906473A8 (pt) Certas entidades químicas, composições e métodos
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
BR112012023021A2 (pt) compostos de indazol e seus usos
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
EA027953B9 (ru) АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
EA201170832A1 (ru) Пуриновые соединения
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MX392150B (es) Moduladores de receptores canabinoides.
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
EA201270428A1 (ru) Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
CU20130155A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
CL2010000497A1 (es) Uso de compuestos derivados de indol para el tratamiento del dolor visceral; compuestos específicos derivados de indol; procedimiento de preparación de un compuesto; composición farmacéutica y uso para el tratamiento de una condición causada por la acción de nos.
UA111331C2 (uk) Пероральний склад, який містить 5-азацитидин, і спосіб його використання
UA107707C2 (en) The use of inhibitors of bruton's tyrosine kinase (btk)